Intranasal Versus Oral Treatments for Allergic Rhinitis: A Systematic Review With Meta-Analysis

J Allergy Clin Immunol Pract. 2024 Dec;12(12):3404-3418. doi: 10.1016/j.jaip.2024.09.001. Epub 2024 Sep 7.

Abstract

Background: Treatments for allergic rhinitis include intranasal or oral medications.

Objective: To perform a systematic review with meta-analysis comparing the effectiveness of intranasal corticosteroids or antihistamines versus oral antihistamines or leukotriene receptor antagonists in improving allergic rhinitis symptoms and quality of life.

Methods: We searched four bibliographic databases and three clinical trial datasets for randomized controlled trials (1) assessing patients aged 12 years and older with seasonal or perennial allergic rhinitis, and (2) comparing intranasal corticosteroids or antihistamines versus oral antihistamines or leukotriene receptor antagonists. We performed a meta-analysis of the Total Nasal Symptom Score (TNSS), Total Ocular Symptom Score, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), development of adverse events, and withdrawals owing to adverse events. Certainty of evidence was assessed using Grading of Recommendations, Assessment, Development, and Evaluation.

Results: We included 35 studies, most of which assessed patients with seasonal allergic rhinitis and displayed an unclear risk of bias. Superiority of intranasal treatments was found for all assessed outcomes. Intranasal corticosteroids were more effective than oral antihistamines at improving the TNSS (mean difference [MD], -0.86; 95% CI, -1.21 to -0.51; I2 = 70%), Total Ocular Symptom Score (MD, -0.36; 95% CI, -0.56 to -0.17; I2 = 0%), and RQLQ (MD, -0.88; 95% CI, -1.15 to -0.61; I2 = 0%), which were mostly associated with clinically meaningful improvements. Superiority of intranasal corticosteroids at improving the TNSS was also found against oral leukotriene receptor antagonists (MD, -1.05; 95% CI, -1.33 to -0.77). Intranasal antihistamines were more effective than oral antihistamines at improving the TNSS (MD, -0.47; 95% CI, -0.81 to -0.14; I2 = 0%) and RQLQ (MD, -0.31; 95% CI, -0.56 to -0.06; I2 = 0%).

Conclusions: Randomized controlled trials suggest that intranasal treatments are more effective than oral treatments at improving symptoms and quality of life in seasonal allergic rhinitis.

Keywords: Allergic rhinitis; GRADE approach; Intranasal antihistamines; Intranasal corticosteroids; Leukotriene receptor antagonists; Meta-analysis; Oral antihistamines.

Publication types

  • Systematic Review
  • Meta-Analysis
  • Comparative Study

MeSH terms

  • Administration, Intranasal*
  • Administration, Oral
  • Adrenal Cortex Hormones* / administration & dosage
  • Adrenal Cortex Hormones* / therapeutic use
  • Anti-Allergic Agents / therapeutic use
  • Histamine Antagonists* / therapeutic use
  • Humans
  • Leukotriene Antagonists / therapeutic use
  • Quality of Life*
  • Randomized Controlled Trials as Topic
  • Rhinitis, Allergic* / drug therapy
  • Rhinitis, Allergic, Seasonal / drug therapy
  • Treatment Outcome

Substances

  • Histamine Antagonists
  • Adrenal Cortex Hormones
  • Leukotriene Antagonists
  • Anti-Allergic Agents